Atara Biotherapeutics Surges 10% Amid FDA Priority Review for Tab-cel

Atara Biotherapeutics (ATRA) shares rallied 10% due to growing investor optimism about its lead product candidate, tabelecleucel, which is under priority review by the FDA. The company is expected to post a quarterly loss of $0.83 per share, a year-over-year change of +71.7%. The consensus EPS estimate has remained unchanged over the last 30 days.